The results indicated that a significant association was existed between metformin and ALT, metformin may decrease the level of ALT in NAFLD patients (MD = −10.84, 95% CI = −21.85 to 0.16, P = .05) (Fig. 2A). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.